Here is the total breakdown of Stendra:
Jan.10 2014;NRx 9, TRx9;Jan.17;NRx265, TRx279; Jan.24;NRx 1353,TRx 1644; Jan.31;NRx 1305 , TRx2982; Feb.7, ; NRx 1787,TRx4820; Feb14,NRx2087,TRx6967;Feb. 21,NRx2334,TRx9412; Feb.28, NRx2751, TRx12,316
Stendra has sat, virtually, ideal for 2 years because Vivus did not have the logistics to properly launch it. The September partnership with Auxilium Pharmaceuticals provided that. These tRX are absolutely live and in-play.
I am long ARNA and VVUS. Stendra launch was 2/28/14, 3/11/14 after bell tRX report 12,316. That is really good.
Ariad has a second-line treatment drug with severe side effects and desperately needs the fiscal and logistical support of a larger pharmaceutical company.
Belviq is superior to Qysmia in regards to current reported efficacy by 2.2% and the Belviq safety profile is vastly superior to Qysmia. Bel-phen clinical results are scheduled out Q3 2014 and product available, as combo Q3 2014. Bel-phen, absolutely destroys the efficacy of Qysmia. That said, both Belviq and Qysmia will have excellent sales.
Stendra will be a blockbuster.
Long ARNA and VVUS.